欢迎访问《中国临床药理学与治疗学》杂志官方网站,今天是

中国临床药理学与治疗学 ›› 2018, Vol. 23 ›› Issue (3): 255-262.doi: 10.12092/j.issn.1009-2501.2018.03.003

• 基础研究 • 上一篇    下一篇

黄芪甲苷对糖尿病大鼠早期肾脏损伤的保护作用及其机制研究

李竹青1,鞠营辉1,陈清青1,马可可1,李卫平1,2   

  1. 1 安徽医科大学药理学教研室,合肥 230032,安徽;2 安庆医药高等专科学校,安庆 246052,安徽
  • 收稿日期:2017-09-14 修回日期:2017-12-19 出版日期:2018-03-26 发布日期:2018-03-28
  • 通讯作者: 李卫平,男,教授,博士生导师,研究方向:内分泌药理学。 Tel: 0551-65161133 E-mail:lwp19@126.com
  • 作者简介:李竹青,女,硕士研究生,研究方向:内分泌药理学。 Tel: 18133621870 E-mail:18133621870@163.com
  • 基金资助:

    国家自然科学基金(81173624);安徽省教育厅自然科学基金(KJ2016SD35)

Protective effects of Astragaloside Ⅳ on early kidney damage in diabetes mellitus rats and its mechanisms

LI Zhuqing 1, JU Yinghui 1, CHEN Qingqing 1, MA Keke 1, LI Weiping 1,2   

  1. 1 Department of Pharmacology, Anhui Medical University, Hefei 230032, Anhui, China; 2 Anqing Medical and Pharmaceutical College, Anqing 246052, Anhui, China
  • Received:2017-09-14 Revised:2017-12-19 Online:2018-03-26 Published:2018-03-28

摘要:

目的: 探讨黄芪甲苷(AS-Ⅳ)对实验性糖尿病大鼠早期肾脏损伤的保护作用及其可能机制。方法:链脲佐菌素(STZ)一次性腹腔注射(55 mg/kg)建立糖尿病大鼠模型,随机分为正常组、模型组、AS-Ⅳ(20、40、80 mg/kg)组。连续给药8周后检测各组大鼠体质量、肾脏指数、血糖、24 h尿微量白蛋白排泄率(24 h UAER)、血肌酐(Scr)、尿素氮(BUN)、血清总超氧化物歧化酶(T-SOD)、谷胱甘肽过氧化物酶(GSH-Px)活性和丙二醛(MDA)含量的变化;HE及PAS染色观察肾脏组织病理学形态学变化;Western blot法检测肾皮质转化生长因子-β1(TGF-β1)、核转录因子E2相关因子2(Nrf2)、血红素氧合酶1(HO-1)蛋白的表达水平。结果: 与正常组比较,模型组大鼠的血糖和肾脏指数以及血清中MDA、Scr、BUN和24 h UAER含量显著升高(P<0.01),T-SOD和GSH-Px活性显著降低(P<0.01),TGF-1、Nrf2总蛋白及核蛋白表达显著增加(P<0.05或P<0.01);与模型组比较,AS-Ⅳ(40、80 mg/kg)组MDA、Scr、BUN、24 h UAER含量显著降低(P<0.01),AS-Ⅳ(80 mg/kg)组T-SOD、GSH-Px活性显著升高(P<0.05或P<0.01),AS-Ⅳ(80 mg/kg)组TGF-1蛋白表达显著降低(P<0.05),Nrf2总蛋白、核蛋白及HO-1蛋白表达显著增加(P<0.05或P<0.01)。结论:AS-Ⅳ能减轻糖尿病大鼠早期肾脏氧化应激的损伤,其作用机制可能与其提高血清抗氧化能力、降低肾脏组织中TGF-β1蛋白表达、激活Nrf2信号通路,增强抗氧化蛋白HO-1的表达有关。

关键词: 糖尿病, 黄芪甲苷, 转化生长因子-β1, 核转录因子E2相关因子

Abstract:

AIM: To study the effects of Astragaloside Ⅳ (AS-Ⅳ) on early kidney damage and the mechanisms in diabetes mellitus rats induced by Streptozotocin (STZ).  METHODS: The diabetic rats model was established by intraperitoneal injection with STZ (55 mg/kg) and the model rats were randomly divided into model group,AS-Ⅳ (20, 40, 80 mg/kg) group. After 8 weeks of administration, body weight, blood glucose, 24 hours urinary protein excretion rate (24 h UAER), the level of serum creatinine (Scr), urea nitrogen (BUN) , serum SOD, GSH-Px activity and MDA content were measured. HE and PAS staining were used to observe renal histopathology and Western blot was used to detect the expression of TGF-β1, Nrf2 and HO-1.RESULTS:Compared with control group, the blood glucose, kidney index, MDA content and the level of Scr, BUN, 24 h UAER and expression of TGF-β1, total protein of Nrf2 and nucleus protein of Nrf2 increased significantly and the serum SOD and GSH-Px activity decreased significantly in diabetes mellitus model group. Compared with model group, AS-Ⅳ(40, 80 mg/kg) group could decrease MDA content , the level of Scr, BUN, 24 h UAER and increase serum SOD and GSH-Px activities, expression of TGF-β1 was decreased by AS-Ⅳ(80 mg/kg) group, expression of total Nrf2, nucleus Nrf2 and HO-1 were increased by AS-Ⅳ(80 mg/kg) group.CONCLUSION:AS-Ⅳ can inhibit renal oxidative stress injury. The meachanism may be related to increasing the serum antioxidant activity and reducing the expression of TGF-β1, activation of Nrf2 pathway, upregulating the expression of antioxidative protein in HO-1.

Key words: diabetes mellitus, astragaloside Ⅳ, TGF-β1, Nrf2

中图分类号: